Cancer Genomics

& Therapeutics Laboratory
CGTL

About
Cancer Genomics and Therapeutics Laboratory

Pioneering cancer research through genomic exploration and innovative therapeutic approaches at Mahatma Gandhi Central University, Motihari

Our Mission

Advancing Cancer Research at the Genomic Frontier

At the Cancer Genomics and Therapeutics Laboratory (CGTL), our mission is to advance the understanding of cancer at the genomic level and develop novel therapeutic strategies to improve patient outcomes. We combine cutting-edge genomic technologies with computational approaches to identify molecular mechanisms underlying cancer initiation, progression, and treatment resistance.

We believe in a highly collaborative and interdisciplinary approach to cancer research. Our laboratory brings together researchers with expertise in molecular biology, genetics, computational biology, and clinical oncology. We work closely with clinical partners to ensure our research addresses the most pressing challenges in cancer treatment and has a clear path to clinical translation.

Our Approach

We employ a multi-disciplinary strategy that bridges bench science with computational analysis. By integrating genomic data with advanced bioinformatics and machine learning, we uncover actionable insights that drive the development of precision oncology approaches tailored to specific cancer subtypes and patient populations.

Clinical Translation

Our research is ultimately aimed at improving patient care. We collaborate with clinical partners to validate our discoveries in patient-derived models and clinical cohorts, ensuring that our genomic insights translate into meaningful therapeutic advances and diagnostic tools.

Research Focus

Areas of Investigation

Our research spans four interconnected domains that collectively advance the fight against cancer.

Cancer Genomics & Molecular Profiling

Identifying differentially expressed genes, mutations, and molecular alterations across cervical, breast, gastric, and gallbladder cancers using GEO and TCGA datasets — revealing key drivers of tumorigenesis and drug resistance.

Targeted Therapeutics & Drug Development

Developing PARP inhibitors for cervical cancer, redox-responsive polymersome drug delivery for breast cancer, and staurosporine-based strategies — from bench to bedside.

Computational Biology & In Silico Analysis

Applying PPI network analysis, Gene Ontology, KEGG pathway enrichment, and survival analysis using Cytoscape, STRING, DAVID, and GEPIA to uncover molecular mechanisms in carcinogenesis.

Cancer Biomarkers & Prognostics

Discovering and validating novel biomarkers — TRIP13, NEK2, TPX2, CTTN, MCM genes, and EMT-associated hub genes — for early detection, prognosis, and treatment monitoring across multiple cancer types.

Facilities

Laboratory Infrastructure

Our laboratory is equipped with state-of-the-art instruments and computational infrastructure to support cutting-edge research in cancer genomics and therapeutics.

Cell Culture

High-Throughput Cell Culture & Drug Screening

State-of-the-art cell culture facilities for drug discovery and validation

Imaging

Advanced Imaging Systems

High-resolution microscopy and imaging for cellular analysis

Computing

Computational Infrastructure

High-performance computing for genomic data analysis

Therapeutics illustration

Therapeutics

Drug screening & validation

Computational illustration

Computational

Bioinformatics & ML pipelines

Biomarkers illustration

Biomarkers

Early detection & diagnosis

Impact

Key Achievements

Our research program has made significant contributions to the field of cancer biology and genomics.

19+

Peer-Reviewed Publications

6+

Cancer Types Studied

3

Active Research Scholars

14+

Years of Research Excellence

Notable Contributions

Novel Cancer Biomarkers

Identification of TRIP13, NEK2, and TPX2 as potential biomarkers for gallbladder cancer early detection

Computational Tools

Development of in silico network analysis approaches for uncovering molecular mechanisms in carcinogenesis

Therapeutic Targets

Preclinical validation of PARP inhibitors and PI3K/AKT pathway as therapeutic targets in cervical cancer

Epigenetic Insights

First evidence of CXCR4 epigenetic silencing promoting metastasis in cervical cancer

Partnerships

Our Collaborations

We collaborate with researchers, clinicians, and institutions worldwide to advance cancer research and therapeutic development.

Host Institution

Mahatma Gandhi Central University

Department of Zoology, MGCU Motihari, Bihar

Research Partners

National & International Research Groups

Collaborative studies in cancer genomics, molecular oncology, and computational biology with research groups across India and internationally.

Clinical Translation

Clinical Partners

Working with clinical oncologists to translate laboratory findings into patient-relevant outcomes and validate biomarkers in clinical cohorts.

Interested in Our Research?

We are always looking for passionate researchers to collaborate with or join our laboratory at Mahatma Gandhi Central University, Motihari.